Gossamer Bio Inc (GOSS)

$0.17 -0.01 (-6.15%)
Market Cap 42.01M
Revenue (ttm) 48.47M
Net Income (ttm) -170.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -351.50%
Debt to Equity Ratio 0.00
Volume 23,415,602
Avg Vol 11,338,216
Day's Range N/A - N/A
Shares Out 234.70M
Stochastic %K 87%
Beta 2.00
Analysts Sell
Price Target $3.80

Company Profile

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to devel...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 684 1300
Address:
3115 Merryfield Row, Suite 120, San Diego, United States
DocKnocks
DocKnocks Jun. 19 at 5:16 PM
$GOSS Why is this in quotes? And obviously nobody knows dude lol 
1 · Reply
Havokmdk
Havokmdk Jun. 19 at 4:53 AM
$GOSS any new on the fda
0 · Reply
zillionaire17
zillionaire17 Jun. 19 at 3:23 AM
$GOSS "Does anyone know roughly what happened with the GOSS FDA meeting results?"
0 · Reply
diggs24
diggs24 Jun. 18 at 7:23 PM
$GOSS Added 10,000@$0.164
0 · Reply
ChasingTheDips
ChasingTheDips Jun. 18 at 7:20 PM
$GOSS if the meeting was good, im hoping the management will make some announcement soon to indicate it went gucci 👀 0.5 coming soon
0 · Reply
DocKnocks
DocKnocks Jun. 18 at 6:56 PM
$GOSS
0 · Reply
neeradampeter
neeradampeter Jun. 18 at 5:41 PM
$GOSS The FDA meeting was likely already held. Now we're just waiting for the official update. If management confirms the September NDA timeline is still on track, I think the market will react very positively. Extreme bullish 😎
0 · Reply
Gunhead01
Gunhead01 Jun. 18 at 2:42 PM
$GOSS will end green today like yesterday
0 · Reply
ChasingTheDips
ChasingTheDips Jun. 18 at 2:20 PM
$GOSS a lot of bag holders existed i assume? it fell off too fast from close .2
0 · Reply
kule04
kule04 Jun. 18 at 1:32 PM
$GOSS why is this rallying? Any news?
1 · Reply
Latest News on GOSS
Gossamer Bio announces final tender results

2026-06-17T12:17:12.000Z - 2 days ago

Gossamer Bio announces final tender results

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Jun 17, 2026, 8:00 AM EDT - 2 days ago

Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio Proxy statement: Proxy filing

Jun 9, 2026, 8:00 AM EDT - 10 days ago

Gossamer Bio Proxy statement: Proxy filing

Gossamer Bio announces early tender results, early settlement of solicitation

2026-06-03T13:13:56.000Z - 16 days ago

Gossamer Bio announces early tender results, early settlement of solicitation

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Jun 3, 2026, 8:00 AM EDT - 16 days ago

Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Gossamer Bio announces extension of early tender date for exchange offer

2026-06-02T13:07:00.000Z - 17 days ago

Gossamer Bio announces extension of early tender date for exchange offer

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Jun 2, 2026, 8:00 AM EDT - 17 days ago

Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes

Investors Sue Gossamer Bio (GOSS) Over Inflated High Blood Pressure Study Claims

2026-05-29T09:38:46.000Z - 21 days ago

Investors Sue Gossamer Bio (GOSS) Over Inflated High Blood Pressure Study Claims

Goldman Sachs suspends rating on Gossamer Bio

2026-05-20T20:11:13.000Z - 4 weeks ago

Goldman Sachs suspends rating on Gossamer Bio

Gossamer Bio price target lowered to 28c from 30c at Barclays

2026-05-19T09:16:47.000Z - 4 weeks ago

Gossamer Bio price target lowered to 28c from 30c at Barclays

Gossamer Bio Earnings Call Transcript: Q1 2026

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Gossamer Bio Earnings Call Transcript: Q1 2026

Gossamer Bio Quarterly report: Q1 2026

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Gossamer Bio Quarterly report: Q1 2026

Gossamer Bio Earnings release: Q1 2026

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Gossamer Bio Earnings release: Q1 2026

Gossamer Bio Slides: Q1 2026

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Gossamer Bio Slides: Q1 2026

Gossamer Bio Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Gossamer Bio Proxy statement: Proxy filing

Gossamer Bio Proxy statement: Proxy filing

May 18, 2026, 8:00 AM EDT - 4 weeks ago

Gossamer Bio Proxy statement: Proxy filing

Gossamer Bio launches exchange offer, consent solicitation

2026-05-18T11:16:03.000Z - 4 weeks ago

Gossamer Bio launches exchange offer, consent solicitation

Gossamer Bio reports Q1 EPS (20c) vs. (16c) last year

2026-05-18T11:06:46.000Z - 4 weeks ago

Gossamer Bio reports Q1 EPS (20c) vs. (16c) last year

Gossamer Bio sees cash runway into 1Q27

2026-05-18T11:05:41.000Z - 4 weeks ago

Gossamer Bio sees cash runway into 1Q27

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

May 18, 2026, 7:05 AM EDT - 4 weeks ago

Gossamer Bio, Inc. Launches Exchange Offer and Consent Solicitation Intended to Eliminate Over $120 Million of Debt with Existing Noteholder Support

Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

May 18, 2026, 7:00 AM EDT - 4 weeks ago

Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

May 15, 2026, 7:01 AM EDT - 5 weeks ago

Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026

Gossamer Bio Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Gossamer Bio Proxy statement: Proxy filing

Gossamer Bio Proxy statement: Proxy filing

Apr 24, 2026, 8:00 AM EDT - 2 months ago

Gossamer Bio Proxy statement: Proxy filing

GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Apr 20, 2026, 4:30 PM EDT - 2 months ago

GOSS Stockholders Have Rights – If You Lost Money Investing in Gossamer Bio, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Gossamer Bio, Inc. (GOSS) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Apr 20, 2026, 11:41 AM EDT - 2 months ago

Gossamer Bio, Inc. (GOSS) Securities Fraud: Contact Berger Montague To Discuss Your Rights

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

2026-03-23T09:15:15.000Z - 3 months ago

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

2026-03-20T20:45:16.000Z - 3 months ago

Gossamer Bio downgraded to Neutral from Overweight at Cantor Fitzgerald

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

Mar 17, 2026, 4:01 PM EDT - 3 months ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

Gossamer Bio Earnings release: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Gossamer Bio Earnings release: Q4 2025

Gossamer Bio Annual report: Q4 2025

Mar 17, 2026, 7:00 AM EDT - 3 months ago

Gossamer Bio Annual report: Q4 2025

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Feb 23, 2026, 11:26 AM EST - 4 months ago

Gossamer Bio Shareholders Are Encouraged to Contact Johnson Fistel for More Information About Potentially Recovering Their Losses

Gossamer Bio Transcript: Study result

Feb 23, 2026, 8:30 AM EST - 4 months ago

Gossamer Bio Transcript: Study result

Gossamer Bio Press release: Study result

Feb 23, 2026, 8:30 AM EST - 4 months ago

Gossamer Bio Press release: Study result

Gossamer Bio Slides: Study result

Feb 23, 2026, 8:30 AM EST - 4 months ago

Gossamer Bio Slides: Study result

Gossamer Bio's experimental lung condition drug fails in late-stage trial

Feb 23, 2026, 8:11 AM EST - 4 months ago

Gossamer Bio's experimental lung condition drug fails in late-stage trial

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Feb 23, 2026, 8:00 AM EST - 4 months ago

Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 8, 2026, 5:30 PM EST - 5 months ago

Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Gossamer Bio to Participate in Upcoming Investor Conferences

Nov 24, 2025, 4:01 PM EST - 7 months ago

Gossamer Bio to Participate in Upcoming Investor Conferences

Gossamer Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 10:00 AM EST - 7 months ago

Gossamer Bio Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 5, 2025, 4:01 PM EST - 8 months ago

Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio Earnings release: Q3 2025

Nov 5, 2025, 7:00 AM EST - 8 months ago

Gossamer Bio Earnings release: Q3 2025

Gossamer Bio Quarterly report: Q3 2025

Nov 5, 2025, 7:00 AM EST - 8 months ago

Gossamer Bio Quarterly report: Q3 2025

Gossamer Bio Transcript: Emerging Growth Conference

Oct 23, 2025, 3:40 PM EDT - 8 months ago

Gossamer Bio Transcript: Emerging Growth Conference

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Sep 25, 2025, 7:41 AM EDT - 9 months ago

Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Sep 25, 2025, 7:31 AM EDT - 9 months ago

Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Sep 22, 2025, 7:31 AM EDT - 9 months ago

Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025

Gossamer Bio Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:10 AM EDT - 10 months ago

Gossamer Bio Transcript: Cantor Global Healthcare Conference 2025

Gossamer Bio to Present at Upcoming Investor Conferences

Aug 29, 2025, 7:31 AM EDT - 10 months ago

Gossamer Bio to Present at Upcoming Investor Conferences

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Aug 5, 2025, 4:01 PM EDT - 11 months ago

Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update

Gossamer Bio Earnings release: Q2 2025

Aug 5, 2025, 4:00 PM EDT - 11 months ago

Gossamer Bio Earnings release: Q2 2025

Gossamer Bio Quarterly report: Q2 2025

Aug 5, 2025, 4:00 PM EDT - 11 months ago

Gossamer Bio Quarterly report: Q2 2025

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Jun 16, 2025, 7:31 AM EDT - 1 year ago

Gossamer Bio Announces Completion of Enrollment in Registrational Phase 3 PROSERA Study for the Treatment of PAH

Gossamer Bio Transcript: Emerging Growth Conference 82

May 22, 2025, 4:25 PM EDT - 1 year ago

Gossamer Bio Transcript: Emerging Growth Conference 82

Gossamer Bio Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Gossamer Bio Earnings Call Transcript: Q1 2025

Gossamer Bio Earnings release: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Gossamer Bio Earnings release: Q1 2025

Gossamer Bio Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Gossamer Bio Quarterly report: Q1 2025

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

May 15, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces First Quarter 2025 Financial Results and Provides Business Update, Including Closure of New Patient Screening in Phase 3 PROSERA Study

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

May 12, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 15, 2025

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

May 7, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio to Present Preclinical Data at the American Thoracic Society (ATS) 2025 International Conference

Gossamer Bio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Gossamer Bio Proxy statement: Proxy Filing

Gossamer Bio Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Gossamer Bio Proxy statement: Proxy Filing

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Mar 13, 2025, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Gossamer Bio Annual report: Q4 2024

Mar 13, 2025, 10:30 AM EDT - 1 year ago

Gossamer Bio Annual report: Q4 2024

Gossamer Bio Earnings release: Q4 2024

Mar 13, 2025, 10:30 AM EDT - 1 year ago

Gossamer Bio Earnings release: Q4 2024

Gossamer Bio Transcript: Barclays 27th Annual Global Healthcare Conference 2025

Mar 12, 2025, 1:00 PM EDT - 1 year ago

Gossamer Bio Transcript: Barclays 27th Annual Global Healthcare Conference 2025

Gossamer Bio Transcript: Leerink’s Global Healthcare Conference 2025

Mar 11, 2025, 4:20 PM EDT - 1 year ago

Gossamer Bio Transcript: Leerink’s Global Healthcare Conference 2025

Gossamer Bio Transcript: Emerging Growth Conference 79

Feb 19, 2025, 12:00 PM EST - 1 year ago

Gossamer Bio Transcript: Emerging Growth Conference 79

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Feb 3, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio Presented Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Jan 28, 2025, 7:01 AM EST - 1 year ago

Gossamer Bio to Present Clinical and Preclinical Data at the Pulmonary Vascular Research Institute 2025 Annual Congress

Gossamer Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024, 9:30 AM EST - 1 year ago

Gossamer Bio Transcript: Piper Sandler 36th Annual Healthcare Conference

Gossamer Bio Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Nov 11, 2024, 10:30 AM EST - 1 year ago

Gossamer Bio Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 4:03 PM EST - 1 year ago

Gossamer Bio Announces Third Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Earnings release: Q3 2024

Nov 7, 2024, 3:00 PM EST - 1 year ago

Gossamer Bio Earnings release: Q3 2024

Gossamer Bio Quarterly report: Q3 2024

Nov 7, 2024, 3:00 PM EST - 1 year ago

Gossamer Bio Quarterly report: Q3 2024

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Aug 26, 2024, 4:01 PM EDT - 1 year ago

Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA CVKD ELUT EUDA GDTC GOVX IMRN

Gossamer Bio Slides: FY 2024

Aug 14, 2024, 1:42 PM EDT - 2 years ago

Gossamer Bio Slides: FY 2024

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces Second Quarter 2024 Financial Results and Provides Business Update

Gossamer Bio Quarterly report: Q2 2024

Aug 12, 2024, 10:01 AM EDT - 2 years ago

Gossamer Bio Quarterly report: Q2 2024

Gossamer Bio Earnings release: Q2 2024

Aug 12, 2024, 10:01 AM EDT - 2 years ago

Gossamer Bio Earnings release: Q2 2024

Gossamer Bio Transcript: Presents at Goldman Sachs 45th Annual Global Healthcare Conference

Jun 12, 2024, 1:20 PM EDT - 2 years ago

Gossamer Bio Transcript: Presents at Goldman Sachs 45th Annual Global Healthcare Conference

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

May 14, 2024, 4:01 PM EDT - 2 years ago

Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 4:01 PM EDT - 2 years ago

Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update

DocKnocks
DocKnocks Jun. 19 at 5:16 PM
$GOSS Why is this in quotes? And obviously nobody knows dude lol 
1 · Reply
Havokmdk
Havokmdk Jun. 19 at 4:53 AM
$GOSS any new on the fda
0 · Reply
zillionaire17
zillionaire17 Jun. 19 at 3:23 AM
$GOSS "Does anyone know roughly what happened with the GOSS FDA meeting results?"
0 · Reply
diggs24
diggs24 Jun. 18 at 7:23 PM
$GOSS Added 10,000@$0.164
0 · Reply
ChasingTheDips
ChasingTheDips Jun. 18 at 7:20 PM
$GOSS if the meeting was good, im hoping the management will make some announcement soon to indicate it went gucci 👀 0.5 coming soon
0 · Reply
DocKnocks
DocKnocks Jun. 18 at 6:56 PM
$GOSS
0 · Reply
neeradampeter
neeradampeter Jun. 18 at 5:41 PM
$GOSS The FDA meeting was likely already held. Now we're just waiting for the official update. If management confirms the September NDA timeline is still on track, I think the market will react very positively. Extreme bullish 😎
0 · Reply
Gunhead01
Gunhead01 Jun. 18 at 2:42 PM
$GOSS will end green today like yesterday
0 · Reply
ChasingTheDips
ChasingTheDips Jun. 18 at 2:20 PM
$GOSS a lot of bag holders existed i assume? it fell off too fast from close .2
0 · Reply
kule04
kule04 Jun. 18 at 1:32 PM
$GOSS why is this rallying? Any news?
1 · Reply
2damoon84
2damoon84 Jun. 18 at 1:16 PM
$GOSS PT for today? God I fucking love losing money.
0 · Reply
Dmm1234
Dmm1234 Jun. 18 at 1:07 PM
$ADTX and $GOSS to the 🌙
0 · Reply
financiallylacking
financiallylacking Jun. 18 at 12:41 PM
$GOSS Big pre market volume. Might be an interesting day.
0 · Reply
Havokmdk
Havokmdk Jun. 18 at 11:43 AM
$GOSS l voted no also good luck People, hopefully we getting good news.Then maybe I'll vote yes
0 · Reply
redbeamgold
redbeamgold Jun. 18 at 10:46 AM
$GOSS just got my voting email and voted no on everything
0 · Reply
steve1947
steve1947 Jun. 18 at 8:15 AM
$GOSS Bullish. We've got this 👍
0 · Reply
Havokmdk
Havokmdk Jun. 18 at 7:55 AM
$GOSS 🤞🤞
0 · Reply
Partyflags
Partyflags Jun. 18 at 6:40 AM
$GOSS
0 · Reply
DocKnocks
DocKnocks Jun. 17 at 11:44 PM
$GOSS… so hot right now
0 · Reply
Havokmdk
Havokmdk Jun. 17 at 10:26 PM
$GOSS
0 · Reply
Bullishontherize
Bullishontherize Jun. 17 at 10:13 PM
$GOSS Reported for spreading false information over and over again without any proof. You should all do the same.
2 · Reply
Processresult
Processresult Jun. 17 at 9:24 PM
$GOSS "REVERSE SPLIT" "WAS" "APPROVED" "YESTERDAY"... "REVERSE SPLIT" "ANNOUNCEMENT" "AT ANY MOMENT"... "GOSSAMER BIO'S" "TYPE B FDA MEETING" IS "JUST" A "FORMALITY" FOR "REJECTION"... THERE IS "NO" 🚫 "WAY' THE "FDA" "WILL" "GRANT" "GOSSAMER BIO" A "NDA" "SUBMISSION"... "BECAUSE" THAT "WILL" "CAUSE" THE "FDA" TO "GET" "SUED"... "BECAUSE" "GOSSAMER BIO" "MISSED" THEIR "PRIMARY ENDPOINT" IN THEIR "PHASE 3" "PROSERA" "CLINICAL" "TRIAL"
1 · Reply